A5091626576- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Diagnosis and treatment of tuberculosis
- HIV Research and Treatment
- Cancer therapeutics and mechanisms
Tongliao Academy of Agricultural Sciences
2022-2023
Beijing Chest Hospital
2021
Capital Medical University
2021
Tuberculosis (TB), which is caused by Mycobacterium tuberculosis (Mtb), remains a major cause of morbidity and mortality worldwide. Increasing lines evidence indicate that certain individuals, are termed resisters, naturally resistant to TB infection. The resister phenotype has been linked host efficient innate immune responses, but the underlying mechanisms key factors remain unclear. Here, we find upon Mtb infection, monocyte-derived macrophages (MDMs) from resisters exhibited distinctly...
ABSTRACT The 2022 World Health Organization guidelines recommend use of two core anti-tuberculosis (TB) drugs, bedaquiline (BDQ) and clofazimine (CFZ), for treatment drug-resistant (DR)-TB. However, several mutated Mycobacterium tuberculosis (MTB) genes, conferring BDQ CFZ resistance, have been reported that predominantly arose from sporadic mutations not comprehensively characterized. Herein, MTB clinical isolates collected drug-susceptible (DS)-, multidrug-resistant (MDR)-, extensively...
Delamanid (DLM) and pretomanid (PTM) are recent additions to the anti-tuberculosis (TB) drug armamentarium, they offer more effective options for drug-resistant TB treatment. In particular, DLM is included in Group C, which recommended use longer multidrug-resistant (MDR)-TB regimens.